Gapping down
In reaction to disappointing earnings/guidance: MERU -16.3%, AFOP -14.4%, HLF -11.8%, TTS -8.6%, GNC -7.9%, NCLH -3.8%, UPS -3.1%, PCL -2.9%, WYNN -2.8%, ETN -2.7%, RYN -1.9%, BP -1.6%, AET -1.5%, LXRX -1.4%, EMN -0.8%, WM -0.8%, TLM -0.6%.
Select solar names showing weakness: YGE -2.9%, JASO -1.9%, JKS -1.1%, CSIQ -0.9%.
Other news: TRGT -24% (to discontinue TC-5214 overactive bladder program; TC-5214 demonstrated mixed results on the co-primary endpoints), KBIO -11.9% (provided update on KB001-A partnership and clinical status; regains global rights to KB001-A from Sanofi Pasteur; announces completion of enrollment in KB001-A Phase 2 cystic fibrosis study), LOCO -8.7% (continued crazi-ness trade in pre-mkt activity), TCPC -3.4% (announced public offering of 5.4 mln common shares), SPEX -3.4% (announces summary of the co's legal proceedings), BDN -3.2% (commenced public offering of 18 mln common shares), ITC -2.7% (still checking), PT -1.3% (still checking), CRWS -1.2% (announced licensing agreement with Carter's (CRI) for infant bedding), ASML -1.2% (STM peer, potentially related to STM downgrade).
Analyst comments: HZNP -3.8% (downgraded to Neutral from Overweight at Piper Jaffray), PCL -2.9% (downgraded to Mkt Perform from Outperform at Raymond James), STM -1.3% (downgraded to Underperform from Mkt Perform at Bernstein), AWI -1.3% (removed from Conviction Buy list at Goldman), DLTR -1.2% (downgraded to Mkt Perform from Outperform at BMO Capital Mkts), THOR-1.1% (downgraded to Market Perform from Outperform at Wells Fargo).
In reaction to disappointing earnings/guidance: MERU -16.3%, AFOP -14.4%, HLF -11.8%, TTS -8.6%, GNC -7.9%, NCLH -3.8%, UPS -3.1%, PCL -2.9%, WYNN -2.8%, ETN -2.7%, RYN -1.9%, BP -1.6%, AET -1.5%, LXRX -1.4%, EMN -0.8%, WM -0.8%, TLM -0.6%.
Select solar names showing weakness: YGE -2.9%, JASO -1.9%, JKS -1.1%, CSIQ -0.9%.
Other news: TRGT -24% (to discontinue TC-5214 overactive bladder program; TC-5214 demonstrated mixed results on the co-primary endpoints), KBIO -11.9% (provided update on KB001-A partnership and clinical status; regains global rights to KB001-A from Sanofi Pasteur; announces completion of enrollment in KB001-A Phase 2 cystic fibrosis study), LOCO -8.7% (continued crazi-ness trade in pre-mkt activity), TCPC -3.4% (announced public offering of 5.4 mln common shares), SPEX -3.4% (announces summary of the co's legal proceedings), BDN -3.2% (commenced public offering of 18 mln common shares), ITC -2.7% (still checking), PT -1.3% (still checking), CRWS -1.2% (announced licensing agreement with Carter's (CRI) for infant bedding), ASML -1.2% (STM peer, potentially related to STM downgrade).
Analyst comments: HZNP -3.8% (downgraded to Neutral from Overweight at Piper Jaffray), PCL -2.9% (downgraded to Mkt Perform from Outperform at Raymond James), STM -1.3% (downgraded to Underperform from Mkt Perform at Bernstein), AWI -1.3% (removed from Conviction Buy list at Goldman), DLTR -1.2% (downgraded to Mkt Perform from Outperform at BMO Capital Mkts), THOR-1.1% (downgraded to Market Perform from Outperform at Wells Fargo).